Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

2 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • Varnimcabtagene autoleucelRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: DISPERSION FOR INFUSION

    View study and source
  • Varnimcabtagene autoleucelRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: DISPERSION FOR INFUSION

    View study and source

Success Metrics

Active Trials
1(50%)

Phase Distribution

Phase 2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

unknown150%
active_not_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
unknownphase_2

Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy

NCT04778579
active_not_recruitingphase_2

Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001 cells) in children and adolescents aged 0-18 years with CD19+ acute lymphoblastic leukaemia resistant or refractory to treatment.

SYFb382d2df2ce94ead98e170eeccd9a662

Clinical Trials (2)

Showing 2 of 2 trials
NCT04778579Phase 2

Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy

Unknown
SYFb382d2df2ce94ead98e170eeccd9a662Phase 2

Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001 cells) in children and adolescents aged 0-18 years with CD19+ acute lymphoblastic leukaemia resistant or refractory to treatment.

Active Not Recruiting

All 2 trials loaded

Drug Details

Intervention Type
Type not reported
Total Trials
2